Non-pharmaceutical interventions for COVID-19 transiently reduced pneumococcal and <i>Haemophilus influenzae</i> carriage in a cross-sectional pediatric cohort in Southampton, UK

David Cleary(University of Birmingham), Stuart C. Clarke(University Hospital Southampton NHS Foundation Trust), Kyla Hayford(Pfizer (United States)), Stephanie W. Lo(Wellcome Sanger Institute), James Campling(Pfizer (United Kingdom)), Jo Southern(Pfizer (United States)), Bradford D. Gessner(Pfizer (United States)), Saul N. Faust(University Hospital Southampton NHS Foundation Trust), Stephen D. Bentley(Wellcome Sanger Institute), María Lahuerta(Pfizer (United States))

Microbiology Spectrum

July 11, 2024

10.1128/spectrum.00224-24

Cited by 7

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

|The Lancet|2020|5k

The Global Burden of Cancer 2013

|JAMA Oncology|2015|2.8k

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

|The Lancet|2020|2.6k

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

|The Lancet|2017|2.4k

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k